Glycomimetics (GLYC) PT Lowered to $18 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Glycomimetics (GLYC) PT Lowered to $18 at H.C. Wainwright

GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease  

August 2, 2019 8:43 PM EDT

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell... More

GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

August 1, 2019 7:30 AM EDT

Announced completion of enrollment in Pfizers Phase 3 clinical trial evaluating rivipansel, the Companys lead investigational drug candidate, in sickle cell disease (SCD) Enrolled first patient in... More